¾«¶«Ó°Òµ

Bio

Professor Jaime S. King is the John and Marylyn Mayo Chair in Health Law and Professor of Law at the ¾«¶«Ó°Òµ of Auckland,Ìýa Senior Affiliate Scholar to the UCSF/UC Law SF Consortium on Science, Law and Health Policy,Ìýand the Executive Editor of The Source for Healthcare Price and Competition.ÌýShe is also a co-author of Health Law: Cases, Materials, and Problems, 8th ed. (2018).

Professor King’s research examines some of the most complex challenges facing healthcare systems. An advocate for health reform, Professor King focuses on the drivers of healthcare costs, with a special interest in market consolidation and efforts to improve transparency in healthcare pricing. These interests led her to found the Source on Healthcare Price and Competition, a multi-disciplinary web-based resource for information and analysis about healthcare price and competition. She has testified before Congress and state legislative hearings on issues related to healthcare consolidation, price transparency, and medical decision-making.

Professor King also presented her work at the National Academy of Medicine’s Leadership Consortium in 2020 on issues related to consolidation and pricing in health care.ÌýProfessor King and her co-author, Erin Fuse Brown, won the Best Mergers and Antitrust Paper of 2017 presented at the American Antitrust Institute Annual Meeting for their article –ÌýThe Anticompetitive Potential of Cross-Market Mergers, and she was the 2015 recipient of the Hastings Foundation Faculty Award for Outstanding Scholarship.​ She is also the 2020-2022ÌýPresident of the Board of Directors for the American Society of Law, Medicine, and Ethics.

Professor King’s work has been published in Nature, Health Affairs, the New England Journal of Medicine, the UCLA Law Review, the Indiana Law Journal,Ìýthe Journal of Law, Medicine and Ethics,Ìýthe Yale Journal of Health Policy, Law and Ethics, the American Journal of Law and Medicine, Prenatal Diagnosis, Human Reproduction, the William and Mary Policy Review, the UC Law SF Journal, and the Hastings Womens’ Law Journal. Her work has also been referenced in the New York Times, the L.A. Times, the San Francisco Chronicle, the Atlantic Monthly, and Slate Magazine.

Selected Scholarship

Books

• Ìý(West Academic 8th ed. 2018) (with Barry R Furrow, Thomas L Greaney, Robert L. Schwartz, Sandra H Johnson, Timothy S Jost, Erin C. Fuse Brown, Brietta R. Clark, Robert Gatter, & Elizabeth Pendo).

Journal Articles

• Antitrust’s Healthcare Conundrum: Cross-Market Mergers and the Rise of System Power, 74ÌýHastings L.J.Ìý1057 (2023) (with Alexandra D. Montague, Daniel Arnold, & Thomas L. Greaney).ÌýÌý
• How Will Draft Merger Guidelines Impact Health Care Markets?,ÌýHealth Aff. ForefrontÌý(Dec. 13) (with Amy Y. Gu & Katherine L. Gudiksen).Ìý
• In this Together: International Collaborations for Environmental and Human Health, 51ÌýJ.L. Med. & EthicsÌý271 (2023) (with Joanna Manning, & Alistair Woodward).Ìý
• Are State Public Option Health Plans Worth It?, 59ÌýHarv. J. on Legis.Ìý145 (2022) (with Katherine L. Gudiksen & Erin C. Fuse Brown).ÌýÌý
• Do State Bans of Most-Favored-Nation Contract Clauses Restrain Price Growth? Evidence From Hospital Prices, 100ÌýMilbank Q.Ìý589 (2022) (with Daniel R. Arnold, Katherine L. Gudiksen, Brent D. Fulton, & Richard M. Scheffler).Ìý
• The Rise Of Cross-Market Hospital Systems And Their Market Power In The US, 41ÌýHealth Aff.Ìý(11) (with Brent D. Fulton et al.).Ìý
• States’ Merger Review Authority Is Associated With States Challenging Hospital Mergers, But Prices Continue To Increase, 40ÌýHealth Aff.Ìý1836 (2021) (with Brent D. Fulton et al.).Ìý
• The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs, 39ÌýJ. Leg. Med.Ìý95 (2019) (with Katherine L. Gudiksen).Ìý
• California’s Drug Transparency Law: Navigating the Boundaries of State Authority on Drug Pricing, 37ÌýHealth Aff.Ìý1503 (2018).Ìý
• Don’t Hate the Player; Hate the Game, 70ÌýAnnals Emergency Med.Ìý875 (2017) (with Renee Y. Hsia & Brendan G. Carr).ÌýÌý
• The Anti-Competitive Potential of Cross-Market Mergers in Health Care, 11ÌýSt. Louis U. J. Health L. & Pol’yÌý43 (2017) (with Erin C. Fuse Brown).ÌýÌý
• The Double-Edged Sword of Health Care Integration: Consolidation and Cost Control, 92ÌýInd. L.J.Ìý55 (2016) (with Erin C. Fuse Brown).Ìý
• Whole-Genome Screening of Newborns? The Constitutional Boundaries of State Newborn Screening Programs, 137ÌýPediatricsÌýS8 (Supp. 1, 2016) (with Monica E. Smith).Ìý
• Best Ethical Practices for Clinicians and Laboratories in the Provision of Non–Invasive Prenatal Testing, 33ÌýPrenatal DiagnosisÌý656 (2013) (with Megan Allyse et al.).Ìý
• Clarifying Costs: Can Increased Price Transparency Reduce Healthcare Spending?, 4ÌýWm & Mary Pol’y Rev.Ìý319 (2013) (with Morgan A. Muir & Stephanie A. Alessi).Ìý
• Group Health’s Participation In A Shared Decision-Making Demonstration Yielded Lessons, Such As Role Of Culture Change, 32ÌýHealth Aff.Ìý294 (2013) (with Benjamin Moulton).Ìý
• Cell-Free Fetal DNA Testing for Fetal Aneuploidy and Beyond: Clinical Integration Challenges in the U.S. Context, 27ÌýHum. Reprod.Ìý3123 (Nov. 2012) (with Megan Allyse, Lauren C. Sayres, Mary E. Norton & Mildred K. Cho).Ìý
• Living ART, 23ÌýHastings Women’s L.J.Ìý73 (2012).Ìý
• Not this Child: Constitutional Questions in Regulating Non-Invasive Prenatal Genetic Diagnosis and Selective Abortion, 60ÌýUCLA L. Rev.Ìý2 (2012).Ìý
• And Genetic Testing for All . . . The Coming Revolution in Non-Invasive Prenatal Genetic Testing, 42ÌýRutgers L.J.Ìý599 (2011).ÌýÌý
• The Potential of Shared Decision Making to Reduce Health Disparities, 39ÌýJ.L. Med. & EthicsÌý30 (2011) (with Mark H. Eckman & Benjamin W. Moulton).Ìý
• Aligning Ethics with Medical Decision-Making: The Quest for Informed Patient Choice, 38ÌýJ.L. Med. & EthicsÌý85 (2010) (with Benjamin Moulton).Ìý
• Duty to the Unborn: A Response to Smolensky, 60ÌýHastings L.J.Ìý377 (2008).ÌýÌý
• Predicting Probability: Regulating the Future of Preimplantation Genetic Screening, 8ÌýYale J. Health Pol’y L. & EthicsÌý283 (2008).ÌýÌý
• Toward the “Tipping Point”: Decision Aids and Informed Patient Choice, 26ÌýHealth Aff.Ìý716 (May/June 2007) (with Annette M. O’Connor, John E. Wennberg, France Legare, Hilary A. Llewellyn–Thomas, Benjamin W. Moulton, Karen R. Sepucha, & Andrea G. Sodano).Ìý
• Rethinking Informed Consent: The Case for Shared Medical Decision-Making, 32ÌýAm. J.L. & Med.Ìý429 (2006) (with Benjamin W. Moulton).ÌýÌý

Chapters In Books

• ERISA as a Barrier for State Health Care Transparency Efforts, inÌýTransparency in Health and Health CareÌý301 (Carmel Shachar, I. Glenn Cohen, Holly Fernandez Lynch, & Barbara J. Evans eds., Cambridge Univ. Press 2019) (with Erin C. Fuse Brown).Ìý

Newspaper & Magazine Articles

• Promoting Health Care Transparency via State Legislative Efforts,ÌýJAMA Health Forum, Mar. 9, 2020 (with Roslyn Murray & Suzanne Delbanco).Ìý
• Politics and Fetal Diagnostics Collide,ÌýNature, Nov. 1, 2012, at 33.

Other Publications

• A Step Forward for Health Care Market Oversight: Oregon Health Authority’s Health Care Market Oversight Program,ÌýMilbank Memorial Fund ReportÌý(2023) (with Robin Davison et al.).Ìý
• Markets or Monopolies? Considerations for Addressing Health Care Consolidation in California,ÌýCHCF Issue BriefÌý(Dec. 2021) (with Katherine L. Gudiksen & Amy Y. Gu).Ìý
• Mitigating the Price Impacts of Health Care Provider Consolidation,ÌýMilbank Memorial Fund Issue BriefÌý(Sept. 2021) (with Katherine L. Gudiksen & Alexandra D. Montague).Ìý
• State Action to Oversee Consolidation of Health Care Providers,ÌýMilbank Memorial Fund Issue BriefÌý(August 2021) (with Alexandra D. Montague & Katherine L. Gudiksen).Ìý
• Who Can Rein in Health Care Prices? State and Federal Efforts to Address Health Care Provider Consolidation,ÌýMilbank Memorial Fund Issue BriefÌý(June 2021) (with Katherine L. Gudiksen & Alexandra D. Montague).Ìý
• Addressing Health Care Market Consolidation and High Prices,ÌýUrban InstituteÌý(January 2020) (with Robert A. Berenson, Katherine L. Gudiksen, Roslyn Murray & Adele Shartzer).Ìý
• Navigating Legal Challenges to State Efforts to Control Drug Prices: Pharmacy Benefit Manager Regulation, Anti-Price-GougingLaws, and Price Transparency,ÌýNational Academy for State Health PolicyÌý(Sept. 19, 2019) (with Katherine L. Gudiksen & Samuel M. Chang).Ìý
• The Secret of Health Care Prices: Why Transparency Is in the Public Interest,ÌýCalifornia Health Care FoundationÌý(July 2019) (with Katherine L. Gudiksen & Samuel M. Chang).Ìý
• The Legal Dimensions of Genomic Sequencing in Newborn Screening,ÌýThe Ethics of Sequencing Newborns: Recommendations and Reflections, special report, Hastings Center Report 48, no. 4Ìý(2018) (with Rachel L. Zacharias & Monica E. Smith).Ìý
• All-Payer Claims Databases: The Balance between Big Healthcare Data Utility and Individual Health Privacy,ÌýThe Source: UCSF/UC Hastings Consortium on Law, Science and Health PolicyÌý(2017) (with Andrew Kelly).Ìý
• State Actions to Promote and Restrain Commercial Accountable Care Organizations,ÌýMilbank Memorial Fund ReportÌý(October 2015) (with Ann Hollingshead, Brent D. Fulton, & Joshua Rushakoff).Ìý

Dissertations & Theses

• The Regulation of Individual Autonomy in Medical Decision–Making (May 2008) (unpublished Ph. D. thesis, Harvard ¾«¶«Ó°Òµ) (on file with Harvard ¾«¶«Ó°Òµ).

Education

• Harvard ¾«¶«Ó°Òµ
  Ph.D., Health Policy, Concentration in Ethics 2008

• Emory ¾«¶«Ó°Òµ School of Law
  J.D., Law 2001

• Dartmouth College
  BA, Psychology 1998